Biostar to Develop New TCM for Cardiovascular Disease

Biostar Pharma, a traditional Chinese medicine company, signed an R&D pact with Northwest University of Xi'an to develop Danshensu Yibingzhi (IDHP), a Class One drug for the treatment of cardiovascular diseases. The university holds patents to IDHP, which was developed by Professor Xiaohui Zheng, who is affiliated with the university and also serves as Chief Scientist at Biostar. The company invests about 18% of its revenues in R&D. More details.... Stock Symbol: (NSDQ: BSPM) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.